A Bianchi1, S Viaggi, E Chiossi. 1. Epilepsy Centre, Department of Neurology, San Donato Hospital, Arezzo, Italy. bianchi.epigenet@tin.it
Abstract
OBJECTIVE: To evaluate the family history of epilepsy in first degree relatives of probands with epilepsy. METHODS: A sample of 10787 patients with epilepsy with complete information about first degree relatives (parents, siblings and offspring) was selected from the database of the Episcreen Project, the largest Italian observational study on epilepsy. Family history was assessed by: (1) prevalence estimates of epilepsy among proband's relatives, (2) modified cumulative risks (MCR), adjusted using proband's age as censoring time in life tables, (3) standardised morbidity ratios (SMR), using a sub-group of symptomatic epilepsies as control group. RESULTS: Patients (9.1%) had a family history of epilepsy. The overall prevalence of epilepsy among first degree relatives was 2.6%. Idiopathic generalised epilepsies had the highest prevalence (5.3%). Cryptogenetic epilepsies had a lower prevalence (2.1%) than idiopathic epilepsies, but higher then symptomatic epilepsies (1.5%), both in generalised and focal forms (3.8% vs. 2.0% and 1.8% vs. 1.3%). A similar tendency was detected using MCR and SMR, with the higher values of risks/ratios for idiopathic and generalised epilepsies. Probands with idiopathic generalised epilepsies were highly concordant with respect to their relatives' type of epilepsy. Considering other strata factors, risks were higher in proband's epilepsies with an onset less then 14 years of age, while sex played no definite role in differentiating the family history. CONCLUSIONS: The Episcreen model permits a variety of stratification factors to measure family risk, including age at onset, epilepsy localisation and aetiology with a large sample of more than 10,000 probands and 1065/40,544 relatives affected and classified.
OBJECTIVE: To evaluate the family history of epilepsy in first degree relatives of probands with epilepsy. METHODS: A sample of 10787 patients with epilepsy with complete information about first degree relatives (parents, siblings and offspring) was selected from the database of the Episcreen Project, the largest Italian observational study on epilepsy. Family history was assessed by: (1) prevalence estimates of epilepsy among proband's relatives, (2) modified cumulative risks (MCR), adjusted using proband's age as censoring time in life tables, (3) standardised morbidity ratios (SMR), using a sub-group of symptomatic epilepsies as control group. RESULTS:Patients (9.1%) had a family history of epilepsy. The overall prevalence of epilepsy among first degree relatives was 2.6%. Idiopathic generalised epilepsies had the highest prevalence (5.3%). Cryptogenetic epilepsies had a lower prevalence (2.1%) than idiopathic epilepsies, but higher then symptomatic epilepsies (1.5%), both in generalised and focal forms (3.8% vs. 2.0% and 1.8% vs. 1.3%). A similar tendency was detected using MCR and SMR, with the higher values of risks/ratios for idiopathic and generalised epilepsies. Probands with idiopathic generalised epilepsies were highly concordant with respect to their relatives' type of epilepsy. Considering other strata factors, risks were higher in proband's epilepsies with an onset less then 14 years of age, while sex played no definite role in differentiating the family history. CONCLUSIONS: The Episcreen model permits a variety of stratification factors to measure family risk, including age at onset, epilepsy localisation and aetiology with a large sample of more than 10,000 probands and 1065/40,544 relatives affected and classified.
Authors: Anna L Peljto; Christie Barker-Cummings; Vincent M Vasoli; Cynthia L Leibson; W Allen Hauser; Jeffrey R Buchhalter; Ruth Ottman Journal: Brain Date: 2014-01-26 Impact factor: 13.501
Authors: Dalia Kasperaviciūte; Claudia B Catarino; Erin L Heinzen; Chantal Depondt; Gianpiero L Cavalleri; Luis O Caboclo; Sarah K Tate; Jenny Jamnadas-Khoda; Krishna Chinthapalli; Lisa M S Clayton; Kevin V Shianna; Rodney A Radtke; Mohamad A Mikati; William B Gallentine; Aatif M Husain; Saud Alhusaini; David Leppert; Lefkos T Middleton; Rachel A Gibson; Michael R Johnson; Paul M Matthews; David Hosford; Kjell Heuser; Leslie Amos; Marcos Ortega; Dominik Zumsteg; Heinz-Gregor Wieser; Bernhard J Steinhoff; Günter Krämer; Jörg Hansen; Thomas Dorn; Anne-Mari Kantanen; Leif Gjerstad; Terhi Peuralinna; Dena G Hernandez; Kai J Eriksson; Reetta K Kälviäinen; Colin P Doherty; Nicholas W Wood; Massimo Pandolfo; John S Duncan; Josemir W Sander; Norman Delanty; David B Goldstein; Sanjay M Sisodiya Journal: Brain Date: 2010-06-03 Impact factor: 13.501
Authors: Bassel Abou-Khalil; Brian Alldredge; Jocelyn Bautista; Sam Berkovic; Judith Bluvstein; Alex Boro; Gregory Cascino; Damian Consalvo; Sabrina Cristofaro; Patricia Crumrine; Orrin Devinsky; Dennis Dlugos; Michael Epstein; Robyn Fahlstrom; Miguel Fiol; Nathan Fountain; Kristen Fox; Jacqueline French; Catharine Freyer Karn; Daniel Friedman; Eric Geller; Tracy Glauser; Simon Glynn; Kevin Haas; Sheryl Haut; Jean Hayward; Sandra Helmers; Sucheta Joshi; Andres Kanner; Heidi Kirsch; Robert Knowlton; Eric Kossoff; Rachel Kuperman; Ruben Kuzniecky; Daniel Lowenstein; Shannon McGuire; Paul Motika; Gerard Nesbitt; Edward Novotny; Ruth Ottman; Juliann Paolicchi; Jack Parent; Kristen Park; Annapurna Poduri; Neil Risch; Lynette Sadleir; Ingrid Scheffer; Renee Shellhaas; Elliott Sherr; Jerry J Shih; Shlomo Shinnar; Rani Singh; Joseph Sirven; Michael Smith; Joe Sullivan; Liu Lin Thio; Anu Venkat; Eileen Vining; Gretchen von Allmen; Judith Weisenberg; Peter Widdess-Walsh; Melodie Winawer Journal: Clin Trials Date: 2013-07-01 Impact factor: 2.486
Authors: Markus Abt; Theo Dinklo; Andreas Rothfuss; Elisabeth Husar; Robert Dannecker; Katja Kallivroussis; Richard Peck; Lucette Doessegger; Christoph Wandel Journal: Clin Pharmacol Ther Date: 2019-05-31 Impact factor: 6.875